<DOC>
	<DOC>NCT00452673</DOC>
	<brief_summary>The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxane and an anthracycline</brief_summary>
	<brief_title>Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For additional information, please contact the BMS oncology clinical trial information service at 8552160126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. Female with advanced breast cancer previously treated with a taxane and an anthracycline No pleural or pericardial effusion Not receiving anticoagulants</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>